机译：一个强大的敌人：耐碳青霉烯类鲍曼不动杆菌和新兴的非抗生素疗法
Division of Infectious Diseases, Cleveland Clinic Akron General, Akron, OH, USA;
Carbapenem-resistant Acinetobacter baumannii; therapies; hospital-acquired infections; vaccination; decolonizationThe emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) has become a serious global health concern. In the United States; nearly half of A. baumannii strains isolated from patients with healthcare-associated infections are resistant to carbapenems 1. Mortality in patients with CRAB infections is high (approximately 33) and treatment options are limited 2; The cost of treating CRAB is considerable and makes up part of the estimated $2.2 billion spent in the United States annually on antibiotic-resistant infections 3. Despite a growing body of research including the use of synergistic combinations from two or three different classes of antibiotics; the optimal treatment of CRAB remains uncertain. Indeed;
